


17th
ANNUAL
2025
CONFERENCE

WELCOME TO THE 17th NNDC ANNUAL CONFERENCE

Bridging Discovery to Delivery: Next-Gen Approaches to Mental Health Treatment

Cincinnati, OH | September 10-11, 2025

*In collaboration with this year's hosts, the University of Cincinnati, the
Lindner Center of HOPE & Cincinnati Children's Hospital Medical Center*



2723 South State Street, Suite 150, Ann Arbor MI 48104 | www.nndc.org

Table of Contents

Welcome to the 2025 NNDC Annual Conference.....	1
Conference Sponsors.....	2
NNDC Board of Directors.....	3
NNDC Staff.....	4
Agenda.....	5-6
Speaker Biographies.....	7-10
NNDC Members.....	11
Power of the Network.....	12
Myriad / GeneSight Symposium Information.....	13-15
Learner Information + Disclosures	16-18
How to Obtain Your Certificate.....	18
2025 Poster Submissions.....	19-23
2025 Travel Awardees.....	23
The Graduate Layout + Map.....	24
Upcoming Events.....	25
Connect with us!.....	26



Find the plain agenda [here](#) or
use the QR code below:



Welcome to the 2025 NNDC Annual Conference!

Esteemed guests, colleagues, and friends,

It is with great pleasure that we welcome you to the 2025 NNDC Annual Conference. This year's theme is **"Bridging Discovery to Delivery: Next-Gen Approaches to Mental Health Treatment"** and we're excited to discuss the evolving nature of our work. We're thrilled to gather and explore the groundbreaking advancements and innovative approaches that are transforming the landscape of mental health care.

This year's conference title embodies our mission to merge the rigorous methodologies of science, the transformative power of technology, and the essential human element of compassion. We are here to discuss, learn, and collaborate on innovative solutions that address the complexities of mental health in a holistic and inclusive manner.


With a robust agenda, we will hear from leading experts in the fields of neuroscience, psychiatry, psychology, and technology. We look forward to delving into cutting-edge research, examining new therapeutic technologies, and sharing best practices that have the potential to significantly improve the lives of those affected by mental health conditions.

This conference is a platform for building connections, fostering collaboration, and inspiring action. We are here to challenge conventional boundaries, question existing paradigms, and create a future where mental health care is accessible, effective, and compassionate for all.

We encourage you to engage actively, share your insights and reflect on the diverse perspectives that each of our participants brings. Together, we can pave the way for innovations that bridge science, technology, and compassion, making a tangible difference in mental health care.

Thank you for joining us on this important journey. Let's work together to transform these innovations in order to bring hope, healing, and humanity to all who need it.

In learning and collaboration,



Mark Frye, MD

Sagar Parikh, MD



Mark Frye, MD Sagar Parikh, MD



From the NNDC Team

On behalf of the entire NNDC Team, we are pleased to welcome you to Cincinnati, Ohio for the 17th Annual Conference! Each year the conference program highlights the ways the NNDC is uniquely positioned to improve diagnosis and treatment of mood disorders by facilitating knowledge sharing across the nation and expediting next-generation research initiatives – and this year's program is no exception.

Our members are engaging in some of the most innovative and exciting innovation in the field, and the Annual Conference is a great way to connect over that work. We hope your time here is insightful and allows you to create connections to draw upon for years to come. Thank you for joining us and welcome to Cincinnati!

Thank you to our 2025 Sponsors!

Platinum Sponsors



Silver Sponsors



Supporting Sponsors



NNDC Board of Directors

Executive Committee of the Board

Mark Frye, MD (President) • Mayo Clinic
Jair C. Soares, MD, PhD (Vice President) • University of Texas Health Science Center at Houston
C. Neill Epperson, MD (Treasurer) • University of Colorado Anschutz Medical Campus
Melissa DelBello, MD, MS (Secretary) • University of Cincinnati & Lindner Center of HOPE
John F. Greden, MD (Founding Chair) • University of Michigan Eisenberg Family Depression Center
J. Raymond DePaulo, Jr, MD (Immediate Past President) • The Johns Hopkins Mood Disorders Center
Olusola Ajilore, MD, PhD (Member-at-Large) • University of Illinois at Chicago
Faith Gunning, PhD (Member-at-Large) • Weill Cornell Medicine
Stuart Charney, RPH, JD (Board Advisor) • NNDC Advisory Council

Board Members representing Center's of Excellence

Caleb Adler, MD • University of Cincinnati & Lindner Center of HOPE
Jorge Almeida, MD, PhD • University of Texas Austin & The Center for Youth Mental Health
Katherine Burdick, PhD • Brigham & Women's Hospital, Partners HealthCare - Harvard Medical School
David Casey, MD • University of Louisville
Susan K. Conroy, MD, PhD • Indiana University
William Coryell, MD • University of Iowa
Mario Cristancho, MD • University of Pennsylvania
Alfredo Cuellar Barbosa, MD • Autonomous University of Nuevo León
Dimitry Davydow, MD, MPH, FACLP • University of Florida
Joao de Quevedo, MD, PhD • University of Texas at Houston, McGovern Medical School
Marc Dubin, MD, PhD • Weill Cornell Medical College
Rif El-Mallakh, MD • University of Louisville Depression Center
Stefan Fernandez Zambrano, MD • Autonomous University of Nuevo León
Jay Fournier, PhD • The Ohio State University
Fernando Goes, MD • Johns Hopkins Medicine
Adriana Hermida, MD • Emory University
Richard Holbert, MD • University of Florida
Kay Redfield Jamison, PhD • Johns Hopkins University Mood Disorders Center
Anand Kumar, MD, MHA • University of Illinois at Chicago
Scott Langenecker, PhD • The Ohio State University
Brian Mickey, MD, PhD • University of Utah Huntsman Mental Health Institute
Michelle Miller, PhD • Indiana University
Jeffrey Newport, MD, MS • University of Texas Austin & The Center for Youth Mental Health
Michael Ostacher, MD, MPH, MMSc • Stanford University
Sagar Parikh, MD, FRCPC • University of Michigan Eisenberg Family Depression Center
Mark Rapaport, MD • University of Utah Huntsman Mental Health Institute
Natalie L. Rasgon, MD, PhD • Stanford University
Scott L. Rauch, MD • McLean Hospital, Partners HealthCare - Harvard Medical School
Patricio Riva Posse, MD • Emory University
Alan F. Schatzberg, MD • Stanford University
Christopher Schneck, MD • University of Colorado Anschutz Medical Campus
Michael Thase, MD • University of Pennsylvania
Carolyn Turvey, PhD • University of Iowa
Jennifer L. Vande Voort, MD • Mayo Clinic


Member Leadership

Eric Achtyes, MD, MS • Western Michigan University Homer Stryker M.D. School of Medicine
Lena Brundin, MD, PhD • Van Andel Institute
Heather Flynn, PhD • Florida State University
Scott Gaynor, PhD • Western Michigan University
Louis Nykamp, MD • Pine Rest Christian Mental Health Services
Erika Saunders, MD • Penn State Milton S. Hershey Medical Center
Patrick Sullivan, MD, FRANZCP • University of North Carolina at Chapel Hill
Nagy Youssef, MD, PhD • Michigan State University

About the Organization + NNDC Staff Members

The NNDC is a national network of world-class institutions and collaborators united to lift the burden of depression, bipolar and other mental health conditions to advance people's overall wellness. The organization works to transform people's lives through innovations in research, driving care solutions and advancing collective community impact.

Founded in 2008, the NNDC has since grown to 27 members representing the top and most well-regarded psychiatry programs in the nation. Learn more at www.nndc.org.



Leadership + Contact Information



Dr. Matt Samocki
Executive Director

✉ msamocki@nndc.org



Brad Hovermale
Director of Operations

✉ bhovermale@nndc.org



Courtney Soule

Director of Membership, Development
+ Public Relations

✉ csoule@nndc.org



Mary Laffey

Task Group Manager +
Strategy Lead

✉ mlaffey@nndc.org



Rob Vallentine

Strategic Business Advisor

✉ rvallentine@nndc.org



Sagar Parikh, MD

Medical Director



Bailey Rann

Research + Media Specialist

✉ brann@nndc.org

Bridging Discovery to Delivery: Next-Gen Approaches to Mental Health Treatment

NNDC Pre-Conference Summit - Wednesday, September 10, 2025

Time (EST)	Topic	Topic Title	Topic Description	Presenters	Location
9-11am	Closed collaborative networking meeting with a supporting partner organization				Alice Room
11am-Noon	Registration and Lunch Buffet				West + North Prefunction
Noon-1pm	Non-CME Presentation	Collaborative Expansion: Scaling Mental Health Programs for Workplaces and Communities through Strategic Partnerships: A Networked Approach to National Impact through the NNDC	This session will feature innovative, scalable mental health programs from across the network. Presenters will highlight virtual care strategies and a statewide pilot focused on workplace mental health for small businesses.	Matt Mishkind, PhD Helen and Arthur E. Johnson Depression Center at the University of Colorado Rob Vallentine, MBA National Network of Depression Centers Sean Egan, JD Michigan Department of Labor and Economic Opportunity	WKRP Room
	Closed collaborative networking meeting with a Platinum Sponsor				Alice Room
Noon-2pm	CME Presentation	The Resilience Scale Training	This 2-hour training explores resilience using the Brain Story's Resilience Scale Metaphor. Participants will learn to use the scale as a tool to assess, explain, and monitor resilience in others and themselves over time.	Claire Niehaus, MSc Palix Foundation	Beast Amphitheater
Noon-3pm	Non-CME NNDC Task Group Member Open House	An opportunity to meet NNDC Task Group members and learn more about the work being accomplished by the various groups. This promises to be a fun time with great conversation, collaboration and camaraderie. There will also be some private meeting space set aside for Task Groups that want to hold a more formal meeting.			Cincinnatus Ballroom
1-2pm	CME Presentation	Overcoming Barriers to Insurance Coverage: A Role for Clinician Advocacy	Many patients and clinicians accept insurance denials for mental health and substance use care without challenge. Cover My Mental Health, a nonprofit, offers free tools to help overcome these barriers. This presentation introduces those resources and empowers both patients and providers to push back, especially against medical necessity denials.	Joe Feldman, MBA Cover My Mental Health	WKRP Room
	NNDC Advisory Council Meeting				Leonard Baehr Room
2-3pm	Non-CME Presentation	The Reflective Lens: A Team-Based Approach for Transformative Depression Care	This session shares case examples and early outcomes supporting residential, team-based assessment as a powerful intervention for treatment-resistant depression. <i>Graeter's ice cream will be available during this presentation thanks to the Lindner Center of HOPE</i>	Michael Groat, MSc, PhD, Will Hartman III, MD and Molly Pachan, PhD Lindner Center of HOPE	WKRP Room
3-5pm	Genesight-Myriad Genetics Non-CME and Non-Promotional Symposium	Better Outcomes in Psychiatric Treatment: A Clinical Conversation on Pharmacogenomic Testing and Other Tools	This session explores emerging tools—such as pharmacogenomic testing, neuromodulation, and brain imaging—to improve outcomes in mood disorder treatment. Results from the 2025 NNDC Member Survey shows strong clinician interest in these strategies, especially in biomarkers and novel medications. Three expert psychiatrists from the Cincinnati region will lead brief lectures, case studies, and a moderated Q&A on how to integrate these tools into clinical practice. Attendees will have opportunities for direct engagement.	Jeffrey Strawn, MD University of Cincinnati & Cincinnati Children's Hospital Quinton Moss, MD Modern Psychiatry and Wellness, LLC Nelson Rodriguez, MD, FAPA Lindner Center of HOPE Moderator: Ryan Griggs, PhD, MS GeneSight - Myriad Genetics	Cincinnatus Ballroom
5-6pm	NNDC Board of Directors in-person only Meeting				Beast Amphitheater
	Cocktail hour				Rotunda, Central & East Break Areas on 1st Floor
6-8:pm	Dinner Buffet				Cincinnatus Ballroom
Additional Meeting Rooms Available Over the Course of the Day					
1-5pm	Open for private meeting space				Joseph Strauss Room Corn Hole Room
3-5pm	Open for private meeting space				Alice Room Leonard Baehr Room

Bridging Discovery to Delivery: Next-Gen Approaches to Mental Health Treatment

NNDC Academic Research Agenda – Thursday, September 11, 2025

NNDC Academic Research Agenda – Thursday, September 11, 2025				
Time (EST)	Topic	Topic Title/Description	Speakers	Location
7:30-8:30am	Registration + Breakfast Buffet			West + North Prefunction
8:30-9am	Welcome	Welcome Address and NNDC Administrative Updates	NNDC Leadership	Cincinnatus Ballroom
9-9:30am	Symposium: Improving Access to Care with Innovative Service Delivery Models	Strategies for Mental Health Care Delivery in Primary Care (25 min talk, 5 min Q&A)	Mark Williams, MD Mayo Clinic	Cincinnatus Ballroom
9:30-10am		Using Group Medical Visits/Shared Medical Appointments to Improve Access to Care for Bipolar Disorder and Other Psychiatric Disorders: Evaluation of a Novel Service Delivery Model (25 min talk, 5 min Q&A)	Vijay Gorrepati, MD University of Texas Austin	
10-10:15am		Panel Discussion with Audience Feedback (15 min Q&A)	Joining the panel: Joseph Cerimele, MD and Hilja Ruegg, MD, University of Cincinnati Moderator: Sagar Parikh, MD, FRCPC, University of Michigan, NNDC Medical Director	
10:15-10:45am	Break			
10:45-11:15am	Mini-Symposia 1: Suicide Prevention	Transforming Suicide Prevention Through Systems Thinking (25 min talk, 5 min Q&A)	Melissa Young, MA, PsyD and Brian Kurtz, MD Cincinnati Children’s Hospital Medical Center	Cincinnatus Ballroom
11:15-11:45am		How AI is being used for Suicide Prevention (25 min talk, 5 min Q&A)	Emily Haroz, PhD Johns Hopkins University	
11:45am-12:45pm	Lunch Options	General Conference Lunch		Cincinnatus Ballroom
		Mood Outcomes Program Lunch Discussion		Zinzinnati Dining Room
12:45-1:45pm	Poster Session			Fountain Square
1:45-2pm	Afternoon Kickoff	NNDC Administrative Announcements	NNDC Leadership	Cincinnatus Ballroom
2-2:20pm	Hot Topics	Metabolomics Signatures for Anxiety and Depression in Clinical and Epidemiology Studies - Influences of Genome Gut Microbiome and Exposome (15 min talk, 5 min Q&A)	Rima Kaddurah-Daouk, PhD Duke University	Cincinnatus Ballroom
2:20-2:40pm		Spinal Interoceptive Pathways as Therapeutic Targets in Major Depressive Disorder (15 min talk, 5 min Q&A)	Francisco Romo-Nava, MD, PhD Lindner Center of Hope	
2:40-3pm		Early results from the Wellness Discovery Survey - State of Ohio Adversity and Resilience Studies (15 min talk, 5 min Q&A)	Scott Langenecker, PhD Ohio State University	
3-3:15pm	Break			
3:15-4:15pm	Plenary Talk	Narrowing the Gap between Discovery and Impact: Implementation Science and the Dissemination of the Collaborative Care Model (45 min talk, 15 min Q&A)	Christopher Miller, PhD Harvard Medical School Introduction By: Melissa DelBello, MD, MS University of Cincinnati College of Medicine	Cincinnatus Ballroom
4:15-4:30pm	Break			
4:30-5pm	Mini-Symposia 2: New Frontiers	Evidence Over Emotion: What We Really Know about SSRIs in Youth (25 min talk, 5 min Q&A)	Jeffrey Strawn, MD University of Cincinnati College of Medicine	Cincinnatus Ballroom
5-5:30pm		Chemistry and Context: Psychedelic-Assisted Psychotherapy for Depression (25 min talk, 5 min Q&A)	Jamarie Geller, MD, MA University of Michigan	
5:30-6:30pm	Networking Happy Hour			Cincinnatus Ballroom
6:30-8:30pm	Dinner & Awards	Travel and poster awardees are celebrated		

Speaker Biographies

Plenary Speaker: Christopher Miller, PhD

Christopher Miller, PhD is an investigator and clinical psychologist at the VA Boston Healthcare System, Center for Health Optimization and Implementation Research (CHOIR). He is also an Associate Professor of Psychology in the Harvard Medical School Department of Psychiatry.

His research focuses on improving care coordination, advancing team-based mental health care, and expanding the use of the Collaborative Chronic Care Model to better serve individuals with depression, bipolar disorder and severe mental illness. His work is at the forefront of implementation science, ensuring that evidence-based practices are not just developed, but effectively integrated into real-world care.

In recognition of his groundbreaking contributions, he was awarded the Presidential Early Career Award for Scientists and Engineers – the highest honor bestowed by the U.S. government on early-career researchers.



Joseph Cerimele, MD, MPH

University of Cincinnati College of Medicine

Dr. Cerimele's clinical research includes primary care psychiatry in general, the epidemiology and treatment of individuals with bipolar disorder in primary care, and measurement-based care for individuals with bipolar disorder. Dr. Cerimele directs the Psychiatry Health Outcomes Research program in the Department of Psychiatry and Behavioral Neuroscience.

Current clinical responsibilities include delivering consultations and brief-duration care in the UCH Mood Disorders Clinic, and serving as a psychiatric consultant in Collaborative Care in the Hoxworth primary care clinic.

Educational responsibilities include promoting scholarship and clinical research among trainees and junior faculty colleagues in health outcomes research. Additionally, Dr. Cerimele is Deputy Editor at the Journal of the Academy of Consultation-Liaison Psychiatry, and a Fellow of the Academy of Consultation-Liaison Psychiatry.



Jamarie Ann Geller, MD, MA

Michigan Medicine

Dr. Geller is a child, adolescent, and adult psychiatrist and psychotherapist. She is adjunct faculty at the University of Michigan in the Department of Psychiatry and is the clinical director of Pneuma Science.



Vijay Rayalu Gorrepati, MD

The University of Texas at Austin

Vijay Gorrepati, MD, is a board-certified psychiatrist in UT Health Austin's Bipolar Disorder Center. He specializes in the treatment of bipolar disorder, using an evidence-based model that integrates pharmacological therapy with psychotherapy, peer support, and expert consultation. Additionally, Dr. Gorrepati is an assistant professor in the Dell Medical School Department of Psychiatry and Behavioral Sciences at The University of Texas at Austin. Dr. Gorrepati earned his bachelor's degree in biology from The University of Texas at Austin and his medical degree from Texas A&M Health Science Center. He completed a residency in psychiatry at the University of Chicago Medicine. Dr. Gorrepati's clinical interests include mentalization-based interventions and community mental health. His research focuses on novel pharmacological and non-pharmacological treatments for bipolar disorder as well as exploring risk factors, early detection, and the neurocognitive changes that occur over time. He is a member of the International Society for Bipolar Disorders.



Emily E. Haroz, PhD, MA, MHS

Johns Hopkins University

Emily Haroz is an Associate Professor in the Departments of Mental Health and International Health, a psychiatric epidemiologist with training with experience in implementation science. The majority of her work is done in partnership with Indigenous Communities. Her most recent work focuses on developing and implementing AI-supported suicide prevention strategies.



Brian Perry Kurtz, MD

Cincinnati Children's Hospital Medical Center and University of Cincinnati

Dr. Brian Kurtz is a Child and Adolescent Psychiatrist at Cincinnati Children's Hospital Medical Center (CCHMC) and an Associate Professor at the University of Cincinnati College of Medicine. Dr. Kurtz served as Director of Child and Adolescent Psychiatry Consultation-Liaison Services for 11 years and has been the Program Director for the Child and Adolescent Psychiatry Fellowship Program at Cincinnati Children's since 2019. Dr. Kurtz's research and clinical interests include youth suicide prevention, education about youth mental health for clinicians in a wide range of disciplines, and consultation-liaison psychiatry and the medical-psychiatric interface.



Scott Langenecker, PhD

The Ohio State University

Dr. Langenecker is a clinical neuropsychologist who specializes in assessing and treating mood and anxiety disorders, working at the adolescence to early adulthood transition. This transition offers key windows of opportunity where new learning can occur and resilience skills can develop, but also where there is increased risk for emergence or worsening of brain illnesses. Dr. Langenecker's work includes developing and adapting innovative biological, technological and cognitive tools to better identify, support and treat youth with mood disorders. The ultimate goal of this work is to improve and save lives by facilitating and developing skills, experiences and supports for meaning, purpose, and connection.



Francisco Romo-Nava, MD, PhD

Lindner Center of HOPE/University of Cincinnati

Dr. Romo-Nava is a physician-scientist studying the role of brain-body interaction pathways in the context of psychiatric disorders with a "Neuroscience of the Body" approach. His work has a focus on the circadian system and spinal interoceptive pathways in affective and eating disorders.

Dr. Romo-Nava is Associate Chief Research Officer at the Lindner Center of HOPE and Associate Professor at the Department of Psychiatry and Behavioral Neurosciences at the University of Cincinnati. He graduated as MD at the Universidad Autonoma de San Luis Potosi, Mexico. He then completed his residency training in Psychiatry and a clinical fellowship in affective disorders at the National Institute of Psychiatry and the Universidad Nacional Autonoma de Mexico (UNAM) and served as attending Psychiatrist at the Affective Disorders Clinic at the National Institute of Psychiatry. He later served as Vice-Chair of Research at the Department of Psychiatry and Mental Health at the UNAM. He graduated with honors obtaining the PhD in Biomedical Sciences with a focus in neuroscience and hypothalamic integration mechanisms at the Institute for Biomedical Research at the UNAM. He then completed a postdoctoral fellowship at the Division of Bipolar Disorder Research in the Department of Psychiatry and Behavioral Neurosciences at the University of Cincinnati.



Dr. Romo-Nava has been PI and Co-I in several clinical and translational studies and author of scientific publications. He has received several academic distinctions and research grants to fund his research, including a National Institute of Mental Health (NIMH) Phased Innovation R61/33 grant, a NIMH K23 Career Development Award, the 2017 NARSAD Young Investigator Award by the Brain and Behavior Research Foundation, and a 2016 Pilot Translational Research Program Award by the Department of Psychiatry and Behavioral Neurosciences at the University of Cincinnati. He is a Research Co-Lead at the Breakthrough Discoveries for thriving with Bipolar Disorder (BD2) Integrated Network at the Lindner Center of Hope/ University of Cincinnati site. He is also the inventor of USPTO patent #10,857,356 titled "transcutaneous spinal cord stimulation for treatment of psychiatric disorders".

Rima Kaddurah-Daouk, PhD

Duke University Medical Center

Dr. Kaddurah-Daouk is a graduate of the American University of Beirut Department of Biochemistry with subsequent training at Johns Hopkins (worked with Nobel Laureate Hamilton Smith), Massachusetts General Hospital and the Massachusetts Institute of Technology. She has been a seminal force in the development of applications of metabolomics in the medical field. She co-founded the Metabolomics Society and served more than four years as its founding president, helping create a presence and voice for an interactive metabolomics community. She co-founded Metabolon, a leading biotechnology company for applications in metabolomics, and two other biotechnology companies. With significant NIH funding (over 45 grants funded), she established and leads large consortia (more than 120 scientists from over 30 academic institutions).

She leads several initiatives and task groups in Precision Medicine. She has over 220 peer reviewed scientific publications, leads a large number of active NIH grants and has more than 60 patents or patent applications. She is an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of neuropsychiatric diseases.



Hilja Ruegg, MD

University of Cincinnati

Dr Hilja Ruegg is an Assistant Professor with a dual appointment in the departments of Psychiatry & Behavioral Neuroscience and Family & Community Medicine. She received her BA from Mount Holyoke College in Russian and Eurasian Studies in South Hadley, Massachusetts in 2000. Prior to attending medical school, she worked internationally with a non-profit promoting community based women's health and education work in Afghanistan followed by program management in a Federally Qualified Community Health Center in Western Massachusetts. After obtaining her MD at Marshall University School of Medicine in 2011 she completed a residency in combined training in Family Medicine and Psychiatry, graduating in 2016. She is board certified in both Family Medicine and Psychiatry. She serves as the Program Director for the Combined Training Residency at the University of Cincinnati since 2016. Her areas of interest include medical and mental health care for underserved populations and the development of service delivery models for integrated mental health and primary care. She is also interested in the integration of addiction medicine in primary care.



Jeffrey Strawn, MD

University of Cincinnati & Cincinnati Children's Hospital

Dr. Strawn is a tenured Professor of Psychiatry, Pediatrics, and Clinical & Translational Pharmacology at the University of Cincinnati and Cincinnati Children's Hospital. He is the Director of the University of Cincinnati Anxiety Disorders Research Program and the Associate Vice Chair of Research in the Department of Psychiatry & Behavioral Neuroscience at the University of Cincinnati. In addition, he co-directs the Cincinnati Center for Clinical & Translational Science & Training. His research focuses on anxiety and related disorders and the pharmacologic treatment of these disorders. With his collaborators, Dr. Strawn uses neuroimaging, pharmacogenetics, and pharmacologic approaches to predict treatment response and medication tolerability. His work broadly aims to identify the best treatments for individual patients based on patient-specific characteristics and to characterize the trajectory of improvement.

This work has provided a platform for refining treatment targets and identifying treatment response biomarkers in anxiety and related disorders. In his clinical practice, he works with youth with anxiety and related disorders and their families and supervises residents and fellows. Dr. Strawn has authored nearly 250 peer-reviewed publications and co-authored six textbooks, including the best-selling Prescriber's Guide for Children and Adolescents and the forthcoming Deprescriber's Guide. He is a distinguished fellow of the American Academy of Child & Adolescent Psychiatry, has been elected as a member of the American College of Neuropsychopharmacology, and has received multiple awards for teaching, mentorship, and research.



Mark D. Williams, MD

Mayo Clinic

Mark Williams received his MD at the University of Minnesota, residency training in Psychiatry at Mayo with additional boards in CL Psychiatry. He has a second academic appointment in Family Medicine.

He began working to bring mental health services to primary care sites at Mayo over 20 years ago and helped to create a division of Integrated Behavioral health (IBH) at Mayo Rochester. He has published over 65 articles, mostly on topics related to integration of evidence-based care models into primary care and has led efforts to translate care coordination models into primary care clinics both at Mayo and as a part of state and national initiatives.

He currently leads Quality Improvement for Mayo Psychiatry and Psychology while also practicing within primary care as a part of a team of IBH providers.




Melissa Ann Young, PsyD

Cincinnati Children's Hospital Medical Center

Dr. Melissa Young is a Pediatric Psychologist at Cincinnati Children's Hospital Medical Center (CCHMC) and an Assistant Clinical Professor in the Department of Pediatrics at the University of Cincinnati. Dr. Young is a provider within the Comprehensive Dialectical Behavior Therapy (DBT) treatment team at CCHMC and serves as the co-lead Zero Suicide, a priority program of the Mental and Behavioral Health Institute at CCHMC. This initiative aims to prevent suicide among patients through a robust systems approach that includes screening, assessment, evidence-based treatments, and continuous quality improvement.



NNDC Member Sites



The National Network of Depression Centers is comprised of major academic medical centers from around the country. By uniting our Centers of Excellence and our Members in a collaborative network, the strongest players in the field grow stronger. The NNDC combines unparalleled expertise and fully leverages available resources to advance state-of-the-science in the field of mood disorders.

CENTERS OF EXCELLENCE

- Brigham & Women's Hospital - Harvard Medical School
- Emory University
- Indiana University
- Johns Hopkins University Medicine Mood Disorders Center
- Mayo Clinic
- McLean Hospital - Harvard Medical School
- The Ohio State University
- Stanford University
- Universidad Autonoma de Nuevo Leon (UANL)
- University of Cincinnati & Lindner Center of HOPE
- Helen and Arthur E. Johnson Depression Center at the University of Colorado Anschutz Medical Campus
- University of Florida Health, Mood Disorders Program
- University of Illinois at Chicago
- University of Iowa Mood Disorders Center
- University of Louisville Depression Center

- University of Michigan Frances and Kenneth Eisenberg and Family Depression Center
- University of Pennsylvania
- Dell Medical School at The University of Texas at Austin
- The University of Texas Health Science Center at Houston
- University of Utah
- Weill Cornell Medicine

MEMBERS

- Cleveland Clinic
- Florida State University College of Medicine
- Michigan State University & Pine Rest Christian Mental Health Services
- Penn State Health Milton S. Hershey Medical Center
- University of North Carolina at Chapel Hill School of Medicine
- Van Andel Institute, Western Michigan University Homer Stryker M.D. School of Medicine & Western Michigan University

POWER OF THE NETWORK




LINDNER
CENTER OF HOPE

 College of Human Medicine
MICHIGAN STATE UNIVERSITY

 The University of Texas at Austin
Dell Medical School

 University of Colorado
Anschutz Medical Campus

 **Indiana University**

 **PennState**
College of Medicine

 THE OHIO STATE UNIVERSITY

 UNIVERSITY OF
ILLINOIS CHICAGO

 **UNC** | SCHOOL OF
MEDICINE

 **UTHealth Houston**

 **Weill Cornell**
Medicine

 VAN ANDEL
INSTITUTE®

 **CINCINNATI**

 UNIVERSITY OF
LOUISVILLE

 **HARVARD**
MEDICAL SCHOOL

 **Mass General Brigham**

 **EMORY**
UNIVERSITY

FSU | **FLORIDA STATE**
UNIVERSITY

 **JOHNS HOPKINS**
MEDICINE

 **Cleveland Clinic**

 **Stanford**
MEDICINE

 UNIVERSIDAD AUTÓNOMA
DE NUEVO LEÓN

 **MAYO CLINIC**

 **WESTERN**
MICHIGAN
UNIVERSITY®

 **PINE**
REST Christian
Mental Health
Services
pinerest.org

 **HEALTH**
UNIVERSITY OF UTAH

 **Penn Medicine**

 **UNIVERSITY OF**
MICHIGAN

 **UNIVERSITY of**
FLORIDA

Cincinnati, OH, September 10-11

Myriad Genetics sponsored Non-CME and Non-Promotional
Symposium Independent of the NNDC Annual Conference



**Symposium | Better outcomes in psychiatric treatment:
A clinical conversation on pharmacogenomic testing and other tools**

There is a critical need for clinical implementation of therapeutic strategies, biomarkers, or tools that can lead to better outcomes for mood disorder patients. This session will be a clinical conversation covering the who, what, when, why, and how of implementing innovative tools like pharmacogenomic testing into the broader context of mood disorder medicine, using a combination of didactic mini lectures, case studies, and moderated round table Q&A with three expert psychiatrists practicing in the Cincinnati, OH region. Attendees will have the opportunity to interact with the speakers and moderator during the session.

September 10, 2025 | 3:00 - 5:00 PM EST



Ryan Griggs, PhD, MS
Moderator
GeneSight | Myriad Genetics

Quinton Moss, MD
Modern Psychiatry and
Wellness, LLC

Nelson Rodriguez, MD, FAPA
Lindner Center of HOPE

Jeffrey Strawn, MD
University of Cincinnati &
Cincinnati Children's
Hospital

**Give us your
feedback!**



[Anonymous Evaluation Link](#)

**Scroll for more information about
the symposium!**

Myriad Genetics Sponsored Non-CME and Non-Promotional Symposium Independent of the NNDC Annual Conference

TITLE

Better Outcomes in Psychiatric Treatment: A Clinical Conversation on Pharmacogenomic Testing and Other Tools

FORMAT

Non-CME Symposium 3:00-5:00p.m. on Wednesday, September 10, 2025. Moderated panelist Q&A format. One moderator and three panelists. Goal is to develop a panel with diverse backgrounds and research/practice experience that are utilizing or have familiarity with pharmacogenomic testing for psychiatric conditions such as depression. Moderator to provide warm welcome, introduce the session format/trajectory and panelists, and deliver 3–5-minute introduction on pharmacogenomic testing as a tool in depression treatment including level setting the audience on terminology/definitions. Moderator intro followed by targeted questioning of the three panelists. Moderator to close with brief outro. Minimal slides will accompany the session with objectives, questions, key bullet points, evidence overview, supporting material, etc.

DESCRIPTION OF THE PROGRAM

There is a critical need for clinical implementation of therapeutic strategies, biomarkers, or tools that can lead to better outcomes for mood disorder patients. Results from the recent 2025 NNDC Member Survey indicate that clinicians are most interested in learning more about brain imaging or electrical biomarkers of response (e.g., fMRI, EEG), neuromodulation, medications with new or novel biological mechanisms of action (e.g., dextromethorphan/ketamine, KarXT, zuranalone), and pharmacogenomic testing. By predicting the likelihood of reduced efficacy, increased side effect risk, or altered dosing requirements for certain medications based on an individual's genetic makeup, pharmacogenomic testing is a biomarker tool that clinicians can use to help inform their treatment decisions, which can lead to better outcomes for some patients. This session will be a clinical conversation covering the who, what, when, why, and how of implementing innovative tools like pharmacogenomic testing into the broader context of mood disorder medicine, using a combination of didactic mini lectures, case studies, and moderated round table Q&A with three expert psychiatrists practicing in the Cincinnati, OH region. Attendees will have the opportunity to interact with the speakers and moderator during the session.

EDUCATIONAL OBJECTIVES

1. Evaluate the current evidence for clinical utility of pharmacogenomic testing and other innovative tools
2. Understand how to use pharmacogenomic testing and other treatment tools and identify patients that may benefit
3. Learn about the challenges facing clinical implementation of new tools and how evidence and NNDC initiatives can help overcome those challenges

**Myriad Genetics Sponsored Non-CME and Non-Promotional
Symposium Independent of the NNDC Annual Conference**

PANELISTS

Quinton Moss, MD

Board-certified Psychiatrist, CEO & Medical Director of Modern Psychiatry and Wellness, LLC

Dr. Quinton E. Moss Sr, MD, is a board-certified psychiatrist, CEO, and Medical Director of Modern Psychiatry and Wellness LLC, a provider of adult and youth mental health and addiction treatment with several locations in the greater Cincinnati region. Dr. Moss was named a Top Doctor in 2014, 2015, and 2025 by Cincinnati Magazine. He completed dual residency training in Family Medicine and Psychiatry at the University of Cincinnati in 2004 where he was a Ginsberg Scholar. Dr. Moss previously served as assistant professor in both the Family Medicine and Psychiatry Departments at the University of Cincinnati and has helped conduct several research studies on behalf of pharmaceutical companies and the National Institutes of Health. Dr. Moss's expertise involves mental health and wellness, addiction recovery, spirituality, and leadership.

Nelson Rodriguez, MD, FAPA

Staff Psychiatrist, Medical Director of Electroconvulsive Therapy Service, Lead Psychiatrist for Rapid Access Service, Lindner Center of HOPE

Nelson F. Rodriguez, M.D., is the Lead Psychiatrist, Rapid Access Service (RAS) and Medical Director of the Neuromodulation Therapy (ECT, TMS, VNS) service at the Frances and Craig Lindner Center of HOPE (Mason, OH) and is an Assistant Clinical Professor at the University of Cincinnati College of Medicine, Department of Psychiatry and Behavioral Neuroscience. Dr. Rodriguez graduated from the University of Santo Tomas Faculty of Medicine and Surgery (Manila, Philippines) in 1985 with a Doctor of Medicine, where he also completed a Family Medicine residency program, and was Head of the Emergency Department at Ospital ng Makati. He finished his General Psychiatry training as Chief Resident at the Harvard Medical School Consolidated Department of Psychiatry South Shore Program (Brockton/West Roxbury, MA) and completed a Fellowship in Consultation Liaison Psychiatry at The Cambridge Hospital. In 2010, he traveled to Orvieto, Italy to complete a Global Mental Health: Trauma and Recovery certification from Harvard in collaboration with the Instituto de Sanita, Italy and he continues to consult on disaster relief, serving as a member of the Ohio Psychiatric Physicians Association (OPPA) Public Mental Health Committee – Subcommittee on Disasters. Dr. Rodriguez is the recipient of a Presidential Award from Mental Health America of Northern Kentucky, where he served as a Board Member from 2005-2024, was a provider nominee for the 2005 and 2006 Cincinnati Business Courier's Health Care Heroes Awards, and he was listed among America's Top Psychiatrists as ranked by the Consumer Research Council of America from 2002-2007. Most recently, Dr Rodriguez was honored with the 2023 Employee of the Year Award from The Frances and Craig Lindner Center and was a 2024 nominee for the Health Care Worker of the Year from the Ohio Hospital Association.

Jeffrey Strawn, MD

Professor of Psychiatry, Pediatrics, and Clinical Pharmacology, University of Cincinnati & Cincinnati Children's Hospital

See listing in NNDC speaker biographies.

MODERATOR | Ryan Griggs, PhD, MS

Senior Medical Science Liaison, Myriad Genetics

As a Senior Medical Science Liaison with GeneSight at Myriad Genetics, Ryan's mission is to empower mental health treatment by serving as a clinical and scientific resource for clinicians and fostering partnerships with the research and healthcare communities. Ryan strives to achieve better outcomes for patients by delivering educational presentations, consulting with clinicians, and leading collaborative research projects that advance the science and knowledge of pharmacogenomics. Prior to Myriad, Ryan worked in drug discovery at Merck, taught at several academic institutions in the Ohio/Kentucky region, and led diverse teams of international neuroscientists as a PhD and postdoctoral researcher. Ryan holds a bachelor's degree in biomedical science from Drexel University, a master's degree in biotechnology from the University of Pennsylvania, and a doctorate in neurophysiology from the University of Kentucky. He enjoys playing sand volleyball and spending time with his wife, two young children, and dogs Waylon and Darling in Dayton, Ohio.

Learner Notification

National Network of Depressions Centers

2025 NNDC 17th Annual Conference

September 10-11, 2025

Cincinnati, Ohio

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and National Network of Depressions Centers. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Professions in scope for this activity are listed below.

Amedco Joint Accreditation Provider Number: 4008163



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physicians

Amedco LLC designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Amedco LLC designates this activity for a maximum of 6.0 ANCC contact hours.

Psychologists

his course is co-sponsored by Amedco and National Network of Depressions Centers. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and content. Maximum of 6.0 hours.

The following state boards accept courses from APA providers for Psychologists/Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, MA (LEP ONLY), MD, ME, MN, MO, NC, ND, NH, NE, NJ, NM, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WY

MI: Accepts courses from APA for Psychologists. No general CE requirement for Counselors.

OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY

AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

MI MFTs: There are no CE requirements for MFTs in MI.

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY ONLY), OK*, OR, SC, UT, WA, WI, WY

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY



Learner Notification

Social Workers

As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. ASWB Content Level: Intermediate/Advanced. Social workers completing this course receive up to 6.0 continuing education credits.



The following state boards accept courses offering ASWB ACE credit for Social Workers: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NC, ND, NE, NH, NM, NJ, NV, OH, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WI, WV*, WY

OK: Accepts ASWB ACE for live, in-person activities but not for ethics and/or online courses.

WV: Accepts ASWB ACE unless activity is held live in West Virginia.

The following state boards accept courses offering ASWB ACE credit for Counselors: AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, MA (LEP ONLY), MD, ME, MO, ND, NE, NM, NH, NV, OK*, OR, PA, TN, TX, UT, VA, WI, WY

MI: No CE requirement for licensed counselors.

The following state boards accept courses offering ASWB ACE credit for MFTs: AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, MD, ME, MO, NC, NE, NH, NM, NV, OK*, OR, PA, RI, TN, TX, UT, VA, WI, WY

AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

MI: No CE for requirement for licensed MFTs.

The following state boards accept ASWB ACE credit for Addictions Professionals: AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

Objectives: After Attending This Program You Should Be Able To

1. Gain insight into emerging systems and individual solutions related to mood disorder challenges.
2. Obtain new knowledge about the latest research about the use of artificial intelligence in psychiatry, exploring challenges in disseminating psychosocial treatments, novel treatment updates, diversity and equity in women's mental health and hot topics in psychiatry related to depression and mood disorders.
3. Learn, discuss, and explore opportunities to collaborate on initiatives designed to improve outcomes for people suffering from depression and mood disorders.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below (Name, Commercial interest)

Cal Adler	Otsuka, Johnson & Johnson: Speakers Bureau BMS, abbvie:Consultant Johnson & Johnson, Otsuka, BMS, Karuna, Intra-Cellular, Ovi :Research Grant Site Principal Investigator
Laura Cabrera	N/A
Paul Carlson	N/A
Joseph Cerimele	N/A
Melissa DelBello	Allergan, NIMH, Otsuka, Alkermes, PCORI, Pfizer, Shire, Janssen, Sunovion, Johnson & Johnson, Lundbeck, Myriad:Research Grant Site Principal Investigator Alkermes, CMEology, Johnson & Johnson, Medscape, Myriad, Sage:Consultant
Joe Feldman	N/A
Mark Frye	Myriad:Research Grant Overall Principal Investigator Baszucki Group:Research Grant Site Principal Investigator BD2:Consultant

Learner Notification, conflict of interest, cont.

Name	Commercial Interest:Relationship
Marie Gaine	N/A
Jamarie Geller	N/A
Vijay Gorrepati	N/A
Emily Haroz	N/A
Brad Hovermale	N/A
Rima Kaddurah-Daouk	Metabolon, Inc , Chymia:Private Stock Shareholder
Christina Klein	N/A
Brian Kurtz.	N/A
Mary Laffey	N/A
Scott Langenecker	N/A
Devon LoParo	N/A
Christopher Miller	N/A
Leslie Miller	N/A
Sagar Parikh	Otsuka, Biogen, Alkermes, Boehringer Ingelheim:Consultant Janssen, Compass:Research Grant Site Principal Investigator Mensante:Stock Shareholder
Luan Phan	Universal Brain, Cybin, AstraZeneca:Consultant
Francisco Romo-Nava	NIMH:Research Grant Site Principal Investigator University of Cincinnati:Patent Holder
Hilja Ruegg	N/A
Matt Samocki	N/A
Suzanne Sampang	Cincinnati Children's Hospital:Employee
Giselli Scaini	N/A
Courtney Soule	N/A
Jeffrey Strawn	AbbVie, MindMed, Vistagen:Research Grant Site Principal Investigator Vistagen, Supernus, AbbVie, Genomind, Collegium Pharmaceuticals:Scientific/Medical Advisory Board Member Alkermes, MindMed, Boehringer-Ingelheim:Consultant UpToDate, Cambridge University Press, Springer Publishing, Myriad (material support):Other
Rob Vallentine	N/A
Mark Williams	HealthStat:Scientific/Medical Advisory Board Member
Melissa Young	N/A
Brad Hovermale	N/A
Justin Kaiser	N/A

**OBTAIN YOUR
CERTIFICATE
HERE!**



How to Get Your Certificate

1. Go to nndc.cmecertificateonline.com
2. Click on the 2025 NNDC 17th Annual Conference link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com



2025 Annual Conference Poster Session

The posters listed below were submitted in the following categories:

Basic Science

This category features posters dealing with approaches (both biological and psychosocial) to understanding mood disorders, new or repurposed treatments and technologies, monitoring strategies with the potential to improve patient outcomes, or objective measures like biometrics, neuroimaging, bloodwork, or genetics.

Clinical Programs

Unified efforts are the best way to expedite technological innovation, dissemination of new information, and translation of research into clinical practice. Posters in this category showcase multidisciplinary programs, demonstrate the efficacy of collaborations beyond academic boundaries, or deal with clinical assessments like patient questionnaires, clinical diagnoses, or clinical interviews.

Poster Number, Submitter + Title

1-12 NNDC Task Groups

Basic Science Posters

- 13 **NREM Oscillations as a Marker of ECT Response in Major Depression**
Hazal Arpacı - University of Iowa
- 14 **Insular Intrinsic Connectivity as a Potential Stratification Biomarker for TMS Target Selection**
Samantha Baldi - Mass General Brigham - Harvard Medical School
- 15 **Comparative Efficacy of rTMS Targets for Smoking Cessation: A Synthesis of Current Evidence**
Jed Casauay - University of Florida Mood Disorders Program
- 16 **A Pilot Study of Mindfulness Based Cognitive Therapy for Mild Depression in Youth**
Raechel Cooley - University of Cincinnati
- 17 **Social Media Impact on Lived Experience (SMILE) of peripartum women**
Ryan Dunn - University of Cincinnati
- 18 **HPA Axis Genetic Architecture in Women with Depression**
Marie E. Gaine - University of Iowa
- 19 **Abnormal Dynamics of Amygdala-Related Coactivation Network in Youth at Familial Risk for Bipolar Disorder**
Ziyang Gao - University of Cincinnati
- 20 **Depression and Anxiety Severity in Relation to Acceptance and Adoption of a Digital Mental Health Intervention**
Sofia J. Gerlein - Mass General Brigham - Harvard Medical School
- 21 **Longitudinal and Cross-Study Neuroimaging Data in Bipolar Disorder at the University of Iowa: Preliminary Anatomical Findings on Ventricular Enlargement**
Gail Inanna Snyder Harmata - University of Iowa
- 22 **Evaluating the Association of Medicaid Postpartum Depression (PPD) Screening and Coverage Policies with PPD Diagnosis Incidence in the US**
Danielle Johnson - Lindner Center of HOPE
- 23 **Persistent Benefit of Pharmacogenomic Testing on Remission and Response Rates in Patients With Major Depressive Disorder**
Holly L. Johnson - Myriad Genetics



Basic Science Posters, continued

- 24** **Examining the Differential Impact of Anhedonia on Behavioral Motivation for Reward Assessed via the Effort-Expenditure for Rewards Task (EEfRT)**
D. Gage Jordan - The Ohio State University Wexner Medical Center
- 25** **Feasibility of a New Procedure to Identify Catatonia With Sequential Virtual Motor Assessments of People With Depression and Related Conditions**
Neeraj Kadubandi - Johns Hopkins University
- 26** **Mapping the Genetic Architecture and Polygenic Predictability of Mood Disorders among African-ancestry populations: A Scoping Review**
Kwabena Poku Kusi-Mensah - Mayo Clinic
- 27** **Ion Regulatory Biomarkers in Bipolar Disorder and Controls**
Lucas Miozza - University of Louisville
- 28** **Blunted Auditory and Salience Network Responses to Non-Emotional Salient Stimuli in the Depressed Brain**
Madaline Mocchi - University of Iowa
- 29** **Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder | Features of Binge Eating Disorder in Individuals with Bipolar Disorder Participating in a Weight-loss Trial: A Post-Hoc Analysis**
Nicole Mori - University of Cincinnati & Lindner Center of HOPE
- 30** **Associations Between Bisphenol and Paraben Exposure on Mood and Cognition in Postmenopausal Women With and Without Major Depressive Disorder**
Ananya Pani - Mass General Brigham - Harvard Medical School
- 31** **Ketamine Reduces Suicidality Associated Emergency Department Utilization In Patients With Treatment-Resistant Depression**
Edith Liliana Patarroyo Rodriguez - Mayo Clinic
- 32** **Emotion Regulation and Generativity in Older Adults with Mood Disorders**
Sera Kayla Pensoy - Mass General Brigham - Harvard Medical School
- 33** **An Experimental Approach to Evaluate Spinal Interoceptive Pathways as a Novel Therapeutic Target in Major Depressive Disorder**
Phong Phan - University of Cincinnati & Lindner Center of HOPE
- 34** **Depression-Related Brain Circuits Differ Across Neuropsychiatric Disorders and Baseline Severity in Deep Brain Stimulation Patients**
Roi Sar-el - Mass General Brigham - Harvard Medical School
- 35** **Metabolic Predictors of Ketamine Response in Treatment-Resistant Depression: The Role of Plasma Lactate**
Giselli Scaini - UTHealth Houston
- 36** **Aberrant Fronto-Temporo-Limbic Oscillations in Individuals With Depressive Symptoms During Cognitive Conflict Encoding**
Aniruddha Shekara - University of Cincinnati

Clinical Programs Posters

- 37** **Childhood Trauma in Females is Associated With Higher Inflammatory Markers At First Episode Mania & Psychosis**
Dina Nabil Mohamed Ali - Mayo Clinic

Clinical Programs Posters, continued

- 38 **Structural MRI Evidence of Trauma Related Alterations in Bilateral Caudate Nuclei in Youth with Elevated Risk for Bipolar Disorder**
Caleb M. Adler - University of Cincinnati & Lindner Center of HOPE
- 39 **The Association of Childhood Maltreatment and Cognitive Performance in individuals with Bipolar Disorder**
Keyanah Alexis - Mass General Brigham - Harvard Medical School
- 40 **Suicidal ideation in perinatal mothers in home visiting programs**
Robert T. Ammerman - University of Cincinnati College of Medicine
- 41 **Computational Analysis of Spoken Language in Mania**
Ivan Nicolas Ayala - Mayo Clinic
- 42 **Unified Approaches to Maternal Mental Health: Advancing Innovation Through Multidisciplinary Integration**
Ritika Baweja - Penn State Health
- 43 **Measurement-Based Care Outcomes: Evaluating Depressive Symptoms in Children and Adolescents in a Partial Hospitalization Treatment Setting**
Ashley-Marie Berry - Cincinnati Children's Hospital Medical Center
- 44 **Behavioral Strategies to Accomplish Challenging Imaging of People With Major Depressive Disorder**
James Robert Brasic - Johns Hopkins University
- 45 **Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia: Results of the Phase 4 KINET-PRO Study**
Sharon Cahoon-Metzger - Neurocrine Biosciences
- 46 **Individual Housing-Based Socioeconomic Status Is Associated with Medical Multimorbidity in Bipolar Disorder**
Deniz Ceylan - Mayo Clinic
- 47 **Large Language Model Performance in Bipolar Disorder: A Diagnostic and Therapeutic Comparison Using GPT-4o**
Alfredo Bernardo Cuellar-Barboza - Universidad Autonoma de Nuevo Leon
- 48 **Can Brain Stimulation Improve Depression in Autistic Individuals?**
Rana Elmaghraby - Cincinnati Children's Hospital Medical Center
- 49 **Clinical Outcomes of Electroconvulsive Therapy in Individuals With Intellectual Disability and Comorbid Mood or Psychotic Disorders: A Retrospective Chart Review**
Lindsay Erin Golden - University of Iowa
- 50 **Relapse and Service Utilization Rate in First Episode Psychosis and First Episode Mania: A Population-Based Cohort Study**
Tamahara Gonzalez-Campos - Mayo Clinic
- 51 **Pharmacogenomic Testing in Depression Treatment: Results from a Survey of NNDC Centers Members**
Ryan B. Griggs - GeneSight-Myriad Genetics
- 52 **Differences in Cannabis and Cannabidiol-Related Attitudes, Medical Beliefs, and Practices Among U.S. Mental Health Providers From States With and Without Cannabis Legalization**
Christopher J. Hammond - Johns Hopkins University
- 53 **Pilot Project to Test Process of Collection of Patient-Reported Outcome Measures via MyChart for Patients With Bipolar Disorder at the University of Cincinnati's Residents' Mood Clinic**
Taylor Hazelwood - University of Cincinnati & Lindner Center of HOPE

Clinical Programs Posters, continued

- 54 **The Collaborative Care Model to Depression Recovery Center Pathway**
Victoria House - The Ohio State University
- 55 **Interplay of Grayanotoxin and Ion Dysregulation in Induction of Mania in Bipolar Patient**
Muhammad Ibrahim - University of Louisville Depression Center
- 56 **Predicting Suicidal Ideation and Behavior in Pediatric Bipolar Disorder Using Machine-Learning**
Hammza Jabbar Abdl Sattar Hamoudi - UTHealth Houston
- 57 **Maternal Mental Health Outcomes 6-36 months After Stillbirth**
Rana Jawish - University of Utah Huntsman Mental Health Institute
- 58 **Dietary Patterns in Bipolar Disorder: An Exploratory Principal Component Analysis of Self-Reported Diet Quality in a Biobank Cohort**
Sofia J. Jezzini-Martinez - Universidad Autonoma de Nuevo Leon (UANL)
- 59 **Genetic Risk and Childhood Trauma Additively Affect Fronto-Thalamic-Striatal Signaling in Youth with a Family History of Bipolar Disorder: A Dynamic Causal Modeling Study**
Corey Robert Jones - University of Cincinnati
- 60 **The Effect of Statins as Adjunctive Therapy for Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials**
Amauri Vargas Junior - UTHealth Houston
- 61 **Adoption of a Learning Health Network (LHN) Approach to Treating Bipolar Disorder at an Academic Medical Center**
Christina Klein - University of Cincinnati
- 62 **Reducing Restraints on a Child Residential Mood Disorder Unit With a DBT-Informed Visual Skills Plan**
Aaron Lee - Cincinnati Children's Hospital Medical Center
- 63 **Vitamin C Supplementation in the Context of Treatment-Resistant Depression**
Johnice Faith Littlejohn - Western Michigan University Homer Stryker M.D. School of Medicine
- 64 **Exchanging Mental Health Information with Parents of College Students**
Meera Menon - The Ohio State University
- 65 **Socioeconomic Status and Psychosocial Stressors in Bipolar Disorder: Insights from the HOUSES Index**
Jin Hong Park - Mayo Clinic
- 66 **Thyroid Peroxidase Antibodies in Bipolar Disorder: Implications for Clinical Sub-phenotypes and Lithium Response**
Bishnu Deep Pathak - Mayo Clinic
- 67 **Breakthrough Discoveries for thriving with Bipolar Disorder (BD2): Transforming Bipolar Disorder Care Through an Integrated, Data-Driven Network**
Martine Polycarpe - The Milken Institute
- 68 **Clinician Insights Into Mental Health Chatbot Companions in Youth**
Bailey Rann - National Network of Depression Centers
- 69 **Adverse Childhood Experiences, Postpartum Depression, and Racial/Ethnic Disparities in an Urban Maternal Population**
Praewpailin Rich - Rush University Medical Center

Clinical Programs Posters, continued



- 70** **Cincinnati Children's Hospital School-Based Program: A Model for Treatment of Depression and other Mental Health Conditions in Schools by a Hospital System**
Jessica M. Sage - Cincinnati Children's Hospital Medical Center
- 71** **Efficacy, Tolerability, and Safety of Auvelity, an Oral Antidepressant: Data From 3 Clinical Trials**
Charles Shinauer - Axsome Therapeutics
- 72** **Beyond Wait-and-See: Data-Driven Decision Points in Pediatric SSRI, CBT and Combination Treatment**
Julia N. Stimpfl - Cincinnati Children's Hospital Medical Center
- 73** **Update on the National Network of Depression Centers (NNDC) Mood Outcomes Program: Focus on Participating Sites**
Jason Straub - Johns Hopkins University
- 74** **Predicting Antidepressant Response to Adjunctive Cariprazine: A Patient-Level Mega-Analysis of Two Randomized, Placebo-Controlled Trials**
Jeffrey Robert Strawn - University of Cincinnati
- 75** **Comparing Trauma in Inpatient Psychiatric Admissions for Children and Adolescents With and Without Depression**
Elaine Lindsay Teeters - Cincinnati Children's Hospital Medical Center
- 76** **Sequential Multiple Assignment Randomized Trial for Bipolar Depression (SMART-BD): Lessons Learned From the Feasibility Study**
Vitaliy L. Voytenko - Western Michigan University Homer Stryker M.D. School of Medicine
- 77** **Effects of Lipid Peroxidation and Polyunsaturated Fatty Acid Biostatus on Ketamine Response in Treatment-Refractory Depression**
Allison S. Wilson - University of Cincinnati College of Medicine
- 78** **Measurement-Based Care for Bipolar Disorder: Symptoms and Treatment Changes**
Ivy Xue - University of Cincinnati

Congratulations to the... 2025 Young Investigator Travel Awardees

- Hammza Jabbar Abdl Sattar Hamoudi | UT Houston | Poster #56
- Hazal Arpacı | University of Iowa Mood Disorders Center | Poster #13
- Samantha Baldi | Mass General Brigham – Harvard Medical School | Poster #14
- Gail Harmata | University of Iowa Mood Disorders Center | Poster #21
- Rana Jawish | Huntsman Mental Health Institute/University of Utah | Poster #57
- Sofía Jezzini-Martínez | Universidad Autonoma de Nuevo Leon (UANL) | Poster #58
- D. Gage Jordan | The Ohio State University | Poster #24
- Madaline Mocchi | University of Iowa Mood Disorders Center | Poster #28
- Edith Liliana Patarroyo Rodriguez | Mayo Clinic | Poster #31
- Roi Sar-el | Mass General Brigham – Harvard Medical School | Poster #34


Facility Map - The Graduate

floor plans



NNDC Upcoming Events

**2025 BEST PRACTICES CONFERENCE:
OCTOBER 3-4 IN CHICAGO**



**2025 NNDC Best Practices for Mood Disorders in
Collaboration with Mayo Clinic**

REGISTER



2026 Events: In process with more information soon!

**2026 APA RECEPTION
MAY 16 IN SAN FRANCISCO**



More info
coming
soon!

Join us for a
Networking Reception

At the American Psychiatric Association 2026 Annual Meeting
Join us for networking and relationship building opportunities with
NNDC Member sites, guests and staff while you're in town for the APA!

**TBD Location – Working on now!
San Francisco, California**



**2026 BEST PRACTICES CONFERENCE:
OCTOBER 8-10 IN DENVER**



**2026 NNDC Best Practices for Mood Disorders
in Collaboration with Mayo Clinic**



**2026 NNDC ANNUAL CONFERENCE
OCTOBER 19-20 IN AUSTIN**




18th
ANNUAL
2026
CONFERENCE

**CO-HOSTED WITH DELL MEDICAL SCHOOL AT THE
UNIVERSITY OF TEXAS AT AUSTIN**



LET'S CONNECT!


NEWS, EVENTS, UPDATES AND MORE!



GIVE US A FOLLOW!

**WANT TO BE
FEATURED?**

Email Courtney Soule
at csoule@nndc.org



LEARN MORE AT [NNDC.ORG](https://nndc.org)



NATIONAL NETWORK of
DEPRESSION CENTERS